Effects of Simvastatin on Plasma Lipoproteins and Response to Arterial Injury in Wild-Type and Apolipoprotein-E-Deficient Mice

Journal of Vascular Research

Volumn 41, Issue 1, 2004, Pages 75-83

  Choudhury, Robin P ^a,c   Carrelli, Angela L ^a   Stern, Joshua D ^a   Chereshnev, Igor ^a   Soccio, Raymond ^b   Elmalem, Valerie I ^a   Fallon, John T ^a   Fisher, Edward A ^b   Reis, Ernane D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Apolipoprotein E; HMG CoA reductase inhibitor; Intimal hyperplasia; Mice; Restenosis; Statin

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FAST PROTEIN LIQUID CHROMATOGRAPHY; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES COMPARISON; WILD TYPE;

ANGIOPLASTY, BALLOON; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS E; FEMORAL ARTERY; HYPERLIPIDEMIAS; LIPOPROTEINS; MICE; MICE, MUTANT STRAINS; SIMVASTATIN; TUNICA INTIMA;

EID: 1542363192     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076436     Document Type: Article

References (36)

1. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.
2. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
3. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A: Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000;23(suppl 2):B72-B78.
7. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
8. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C, Chiariello M: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000;35:214-221.
9. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890.
10. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM: Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-3024.
11. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F: HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001;21:1165-1171.
12. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M: In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327-1332.
13. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990;343:425-430.
14. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, et al: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995;1:541-545.
15. Everson WV, Smart EJ: Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: Implications for vascular disease. Trends Cardiovasc Med 2001;11:246-250.
16. Gleason MM, Medow MS, Tulenko TN: Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res 1991;69:216-227.
17. Bandoh T, Mitani H, Niihashi M, Kusumi Y, Ishikawa J, Kimura M, Totsuka T, Sakurai I, Hayashi S: Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol 1996;315:37-42.
18. Chen Z, Fukutomi T, Zago AC, Ehlers R, Detmers PA, Wright SD, Rogers C, Simon DI: Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 2002;106:20-23.
19. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:266-276.
20. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-353.
21. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-471.
22. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-121.
23. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED: Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 2000;20:335-342.
24. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA: Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001;104:2447-2452.
25. Bisgaier CL, Essenburg AD, Auerbach BJ, Pape ME, Sekerke CS, Gee A, Wolle S, Newton RS: Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res 1997;38:2502-2515.
26. Steiner S, Gatlin CL, Lennon JJ, McGrath AM, Seonarain MD, Makusky AJ, Aponte AM, Esquer-Blasco R, Anderson NL: Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin. Toxicol Lett 2001;120:369-377.
27. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, et al: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994;331:1331-1337.
28. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol 1997;30:863-869.
29. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
30. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME: Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol, in press.
31. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL: Biliary cholesterol excretion: A novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci USA 1998;95:10194-10199.
32. Mahley RW, Ji Z-S: Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1-16.
33. Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG: Lipoprotein clearance mechanisms in LDL receptor-deficient 'Apo-B48-only' and 'Apo-B100-only' mice. J Clin Invest 1998;102:1559-1568.
34. Brown ML, Yui K, Smith JD, LeBoeuf RC, Weng W, Umeda PK, Li R, Song R, Gianturco SH, Bradley WA: The murine macrophage apoB-48 receptor gene (apoB-48R): Homology to the human receptor. J Lipid Res 2002;43:1181-1191.
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
36. Reis ED, Roque M, Dansky H, Fallon JT, Badimon JJ, Cordon-Cardo C, Shiff SJ, Fisher EA: Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2000;97:12764-12769.